Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- Novartis’ Flawed and Delayed Inquiry Responses in Zolgensma Review “Extremely Unusual”: PMDA Report
April 16, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- MHLW Asks Drug Makers, Wholesalers to Reduce People Coming to Work by “at Least 70%”
April 15, 2020
- Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
- MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
- 15 Insulins, Erleada, Faslodex under PMDA Safety Review
April 13, 2020
- MHLW Urges Drug Makers, Wholesalers to Ensure Stable Drug Supplies amid Emergency
April 10, 2020
- MHLW Plans to Revise National Vaccine Certification Rules in June
April 10, 2020
- League of Lawmakers Urges MHLW to Help COVID-19 Drug/Vaccine Development
April 10, 2020
- Chuikyo Allows Round Robin Meetings for Coronavirus-Related Matters
April 9, 2020
- Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
- PMDA to Accept Trial Notifications by Email amid Coronavirus Outbreak
April 9, 2020
- MHLW Staffer Infected with Novel Coronavirus
April 9, 2020
- Talks with Regulators Ongoing for Ferinject, Zeria Says after Skipping Listing 4 Times
April 9, 2020
- AMED Invites Research Projects for COVID-19 Vaccine Development from Mid-April
April 9, 2020
- World’s 1st Topical JAK Inhibitor Corectim, AbbVie’s Rinvoq, Bayer’s Nubeqa OK’ed for Listing on April 22
April 8, 2020
- Novartis Japan Chided over Flawed Zolgensma Data, Delayed Responses
April 8, 2020
- Japan Books 13.9 Billion Yen to Boost Avigan Stockpile, Abe Vows to Expand Access to Fujifilm Drug
April 8, 2020
- Carcinogen in On-Market Nizatidine Products Acceptable Levels: MHLW
April 6, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…